2022
Antiviral Treatment of Coronavirus Disease-2019 Pneumonia
Radcliffe C, Malinis M, Azar M. Antiviral Treatment of Coronavirus Disease-2019 Pneumonia. Clinics In Chest Medicine 2022, 44: 279-297. PMID: 37085220, PMCID: PMC9701636, DOI: 10.1016/j.ccm.2022.11.008.Peer-Reviewed Original ResearchConceptsAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSyndrome coronavirus 2 infectionCoronavirus diseaseCoronavirus 2 infectionDirect acting antiviralsAdditional clinical trialsReal-world studyCOVID-19Acting antiviralsAntiviral treatmentTherapeutic optionsAvailable therapiesClinical trialsDisease progressionInpatient treatmentHigh riskEarly pandemicMonoclonal antibodiesDiseaseTreatmentMorbidityPandemicPneumoniaOutpatientsMucocutaneous Leishmaniasis in a Pregnant Immigrant
Briggs N, Wei BM, Ahuja C, Baker C, Palacios C, Lee E, O’Grady N, Singanamala S, Singh K, Bandaranayake TD, Cohen JM, Damsky W, Davis MW, Mejia R, Nelson CA, Topal JE, Azar MM. Mucocutaneous Leishmaniasis in a Pregnant Immigrant. Open Forum Infectious Diseases 2022, 9: ofac360. PMID: 35928503, PMCID: PMC9345408, DOI: 10.1093/ofid/ofac360.Peer-Reviewed Original Research
2019
Fungal Immunoepidemiology
Azar M. Fungal Immunoepidemiology. 2019, 179-191. DOI: 10.1007/978-3-030-25553-4_11.Peer-Reviewed Original ResearchFungal infectionsImmune responseImmune defenseHost immune responsePublic health impactImportant fungal infectionsSpecific innateImmunocompetent populationAntifungal vaccinesInvasive mycosesInfectionImmunoepidemiologyFungal recognitionCritical pathwaysHealth impactsDisease susceptibilityAdaptive responseResponseCoccidiomycosisMorbidityPredisposesImmunodeficiencyVaccinePopulationInnate